Elsevier

Psychiatry Research

Volume 225, Issue 3, 28 February 2015, Pages 305-308
Psychiatry Research

Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase

https://doi.org/10.1016/j.psychres.2014.12.020Get rights and content

Highlights

  • Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase.

  • Bcl-2 levels might be an indicator of severity of manic symptoms in bipolar patients in a manic phase.

Abstract

B cell lymphoma protein-2 (Bcl-2) may contribute to the pathophysiology of bipolar disorder, and may be involved in the therapeutic action of anti-manic drugs. The aim of this study was to investigate serum levels of Bcl-2 in bipolar patients in a manic phase, and evaluate the Bcl-2 changes after treatment. We consecutively enrolled 23 bipolar inpatients in a manic phase and 40 healthy subjects; 20 bipolar patients were followed up with treatment. Serum Bcl-2 levels were measured with assay kits. All 20 patients were evaluated by examining the correlation between Bcl-2 levels and Young Mania Rating Scale (YMRS) scores, using Spearman׳s correlation coefficients. The serum Bcl-2 levels in bipolar patients in a manic phase were higher than in healthy subjects, but without a significant difference. The YMRS scores were significantly negatively associated with serum Bcl-2 levels (p=0.042). Bcl-2 levels of the 20 bipolar patients were measured at the end of treatment. Using the Wilcoxon Signed Rank test, we found no significant difference in the Bcl-2 levels of bipolar patients after treatment. Our results suggest that Bcl-2 levels might be an indicator of severity of manic symptoms in bipolar patients in a manic phase.

Introduction

The etiology of bipolar disorder remains unclear, but there is increasing evidence suggesting that it is associated with dysregulation of neurotrophic signaling cascades and apoptosis (Friedrich, 2005, Shaltiel et al., 2007, Uribe and Wix, 2012, Fries et al., 2014, Moutsatsou et al., 2014). The dysregulation of neurotrophic signaling cascades may be related to apoptosis and contribute to brain atrophy in bipolar disorder patients (Lyoo et al., 2004, Kim et al., 2010). B cell lymphoma protein-2 (Bcl-2) has been reported to be related to the pathology of bipolar disorder (Shaltiel et al., 2007, Machado-Vieira et al., 2011, Uemura et al., 2011, Soeiro-de-Souza et al., 2013). In addition, mood stabilizers have neuroprotective effects and can influence bcl-2 protein (Chuang, 2005, Wada et al., 2005, Hammonds and Shim, 2009, Soeiro-de-Souza et al., 2012, Leng et al., 2013).

Apoptosis is triggered through extrinsic and intrinsic (mitochondrial) pathways (Schulze-Osthoff et al., 1992, Wang et al., 2006, Uribe and Wix, 2012). Apoptosis pathways are related to many molecules such as Bcl-2, Bcl-2-associated death promoter (BAD), Bcl-2-associated X protein (BAX) caspase-3, caspase-9 and cytochrome c (Le Bras et al., 2006, Belizario et al., 2007, Guo et al., 2010, Grimm, 2012). The anti-apoptotic protein Bcl-2 prevents mitochondrial release of cytochrome c, which leads to apoptosis (Scorrano and Korsmeyer, 2003, Ohkubo et al., 2007). In addition, Bcl-2 may inhibit neuronal apoptosis and has a neuroprotective effect (Chen et al., 1997, Manji et al., 2000, Lei et al., 2012, Wei et al., 2013). Anti-apoptotic protein Bcl-2 may play a role in the pathophysiology of bipolar disorder (Benes et al., 2006, Kim et al., 2010).

Bcl-2 levels are significantly decreased in the prefrontal cortex of bipolar patients compared to healthy controls (Kim et al., 2010). Moutsatsou et al. (2014) reported increased BAX/Bcl-2 ratios in manic and depressed patients with bipolar disorder comparedto healthy controls. In addition, the Bcl-2 gene single nucleotide polymorphism (SNP) rs956572 was reported to be related to abnormal Bcl-2 gene expression in bipolar patients (Machado-Vieira et al., 2011). Our previous data revealed that there were no significant changes in Bcl-2 levels in schizophrenia patients who were in an acute phase and with 4-week treatment (Tsai et al., 2013). However, there is little data on the association between Bcl-2 level changes and manic episodes in bipolar patients.

The aims of this study were to investigate the serum levels of Bcl-2 in bipolar patients in a manic phase, and to determine the relationship between Bcl-2 levels and Young Mania Rating Scale (YMRS) scores in bipolar patients in a manic phase. In addition, we investigated the changes in Bcl-2 levels in patients after treatment. This was the first study to evaluate Bcl-2 serum levels in bipolar disorder patients.

Section snippets

Patients and study design

All patients with bipolar I disorder in a manic phase were enrolled from the inpatient ward of Kaohsiung Chang Gung Memorial Hospital, and all of them were diagnosed by the same psychiatrist using the Structured Clinical Interview (SCID) and DSM-IV criteria. The YMRS was administered by two board-certified psychiatrists at baseline and at the endpoint of the study to evaluate severity of disease. Data including age, sex, body mass index (BMI: kg/m2), and serum Bcl-2 levels was collected. All

Results

We consecutively enrolled 23 bipolar inpatients in a manic phase and 40 healthy subjects (20 men and 20 women). Three bipolar patients dropped out of the study, leaving 20 patients (12 men and 8 women) who were followed up. The 20 patients had mean hospitalization durations of 25.8±5.0 days. In addition, all the patients had at least YMRS=20 at baseline (Table 3). The serum Bcl-2 levels in the bipolar patients (0.65±0.48 ng/ml) in a manic phase were higher than those in the healthy subjects

Discussion

The most important finding in our study is that the serum Bcl-2 levels of bipolar patients in a manic phase were significantly negatively associated with YMRS scores.

Bcl-2 might have neuronal anti-apoptotic and neuroprotective effects (Manji et al., 2000, Lei et al., 2012, Wei et al., 2013). Oxidative stress causes brain damage in bipolar patients (Wang et al., 2009); therefore, Bcl-2 levels in bipolar patients in a manic phase might decrease. Our result suggested that Bcl-2 levels might be an

Acknowledgments

This work was supported by grants from Chang Gung Memorial Hospital in Taiwan (Research number: CMRPG8B0511) provided to Tsai MC. We did not obtain financial support from any drug company. In addition, Tsai MC and Huang TL conceptualized and designed the study, and formulated the hypotheses and analytical strategies. Chen WT and Tsai MC wrote the manuscript.

References (47)

  • K. Schulze-Osthoff et al.

    Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation

    The Journal of Biological Chemistry

    (1992)
  • L. Scorrano et al.

    Mechanisms of cytochrome c release by proapoptotic BCL-2 family members

    Biochemical and Biophysical Research Communications

    (2003)
  • G. Shaltiel et al.

    Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder

    Current Opinion in Pharmacology

    (2007)
  • N. Song et al.

    Mood stabilizers commonly restore staurosporine-induced increase of p53 expression and following decrease of Bcl-2 expression in SH-SY5Y cells

    Progress in Neuro-Psychopharmacology & Biological Psychiatry

    (2012)
  • M.C. Tsai et al.

    Bcl-2 associated with positive symptoms of schizophrenic patients in an acute phase

    Psychiatry Research

    (2013)
  • E. Uribe et al.

    Neuronal migration, apoptosis and bipolar disorder

    Revista de Psiquiatria y Salud Mental

    (2012)
  • A. Vasconsuelo et al.

    Role of 17beta-estradiol and testosterone in apoptosis

    Steroids

    (2011)
  • A. Wada et al.

    Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases

    Journal of Pharmacological Sciences

    (2005)
  • Y. Wang et al.

    Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway

    The Journal of Biological Chemistry

    (2006)
  • J.J. Warsh et al.

    Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: Current status

    Clinical Neuroscience Research

    (2004)
  • J.M. Adams et al.

    The bcl-2 protein family: arbiters of cell survival

    Science

    (1998)
  • M.T. Beck et al.

    Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R

    Oncogene

    (2002)
  • J.E. Belizario et al.

    A mechanistic view of mitochondrial death decision pores

    Brazilian Journal of Medical and Biological Research

    (2007)
  • Cited by (10)

    • Circulating Bcl-2 concentrations and septic patient mortality

      2021, Enfermedades Infecciosas y Microbiologia Clinica
      Citation Excerpt :

      Decreased expression of Bcl-2 (one member of the anti-apoptotic Bcl-2 family) in white blood cells in septic patients than in control subjects have been found6–10 and in non-survivor than in survivor septic patients has been found.10 Circulating Bcl-2 concentrations have been previously reported in patients with different diseases.11–15 However, there are not data on circulating Bcl-2 concentrations in septic patients.

    • Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator

      2018, Journal of Affective Disorders
      Citation Excerpt :

      Supporting the neuroprotective effects of lithium associated with effects at Bcl-2, upregulation in Bcl-2 levels in the dentate gyrus and hippocampus was observed after four weeks of lithium treatment (Hammonds and Shim, 2009). Bcl-2 has been associated with severity of manic symptoms in bipolar patients in a manic phase (Chen et al., 2015). Bcl-2 is also an essential protein regulating calcium signaling by interacting with different organelles involved in the pathophysiology of BD.

    • A model of the mitochondrial basis of bipolar disorder

      2017, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      We thus turn to the role of apoptotic signaling pathways in the next section of the paper. Bcl-2 is upregulated in patients with mania and its levels are seemingly positively associated with the severity of symptoms (Benes et al., 2005; Chen et al., 2015). The activity of Bcl-2, and B-cell lymphoma-extra large (Bcl-xL) is essential for the maintenance of oxidative phosphorylation and increased activity of Bcl-2 leads to a corresponding increase in mitochondrial respiration and production of ATP (Manfredi et al., 2002).

    • Targeting Mitochondrial Dysfunction for Bipolar Disorder

      2021, Current Topics in Behavioral Neurosciences
    • Biological Targets Underlying the Antisuicidal Effects of Lithium

      2020, Current Behavioral Neuroscience Reports
    View all citing articles on Scopus
    View full text